A triple-peptide blend, known as Coremend, containing TB-500 (25mg), BPC-157 (10mg), and KPV (10mg) 45mg total per vial
140,141,142,143,144 Targeting autocrine/paracrine, and systemic functions: therapeutic considerations GHR antagonism suppresses the endocrine, autocrine, and paracrine functions of GH, and this is an important consideration that has particular relevance for cancer on the basis that both systemic and tumor-derived GH contribute to cancer progression
Fovet T, Guilhot C, Delobel P, Chopard A, Py G, Brioche T
Research-grade peptides are intended for laboratory research only, may contain impurities or inconsistent dosing, lack proper quality control, and carry legal and safety concerns for human use